Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Bevacizumab + XELOX in mCRC
NCT04547166Phase 3Recruiting
- Sponsor
- Henlius
- Start
- Mar 2021
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
A Phase 3 trial of serplulimab in metastatic colorectal cancer (mCRC), sponsored by Henlius. Started Mar 2021; status: recruiting.
02
Drugs
serplulimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04547166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547166.